Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine

Environmental and Molecular Mutagenesis

Volumn 27, Issue 4, 1996, Pages 255-262

  Ferguson, Lynnette R ^a   Whiteside, Glenn ^a   Holdaway, Karen M ^a   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Amsacrine; Aneuploidy; Fluorescence in situ hybridisation; G2 arrest; Polyploidy; Topoisomerase II

Indexed keywords

AMSACRINE; ENZYME INHIBITOR;

ANEUPLOIDY; ARTICLE; CELL CYCLE G2 PHASE; CELL LINE; CELL SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME DAMAGE; CHROMOSOME NUMBER; CYTOTOXICITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENOTOXICITY; HAMSTER; HUMAN; NONHUMAN; POLYPLOIDY;

AMSACRINE; ANALYSIS OF VARIANCE; ANEUPLOIDY; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; CELL LINE; CHO CELLS; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 4; CRICETINAE; CRICETULUS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G2 PHASE; HUMANS; HYBRID CELLS; IN SITU HYBRIDIZATION, FLUORESCENCE; METAPHASE; POLYPLOIDY;

EID: 0030056380     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2280(1996)27:4<255::AID-EM2>3.0.CO;2-C     Document Type: Article

References (19)

1. Arlin ZA (1989): A special role for amsacrine in the treatment of acute leukemia. Cancer Invest 7:607-609.
2. Ashby J, Tinwell H, Poorman-Allen P, Krehl R, Callander RD, Clive D (1994): Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: Comparison to Salmonella responses. Environ Mol Mutagen 24:51-60.
3. Baguley BC (1991): Cell cycling, cdc2 and cancer. J Natl Cancer Inst 83:896-898.
4. Baguley BC, Calveley SB, Harvey VJ (1988): Effects of CI-921, an analogue of amsacrine, on advanced Lewis lung tumours in mice: Relevance to clinical trials. Eur J Cancer Clin Oncol 24:211-218.
5. Charron M, Hancock R (1991): Chromosome recombination and defective genome segregation induced in Chinese hamster cells by the topoisomerase II inhibitor VM-26. Chromosoma 100:97-102.
6. Downes CS, Mullinger AM, Johnson RT (1991): Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis. Proc Natl Acad Sci USA 88:8895-8899.
7. Eastmond DA, Pinkel D (1990): Detection of aneuploidy and aneuploidy-inducing agents in human lymphocytes using fluorescence in situ hybridization with chromosome-specific DNA probes. Mutat Res 234:303-318.
8. Ferguson LR, Baguley BC (1994): Topoisomerase II enzymes and mutagenicity. Environ Mol Mutagen 24:245-267.
9. Ferguson LR, van Zijl P, Baguley BC (1989): Mutagenicity profiles of newer amsacrine analogues with activity against solid tumours: Comparison of microbial and mammalian systems. Eur J Cancer Clin Oncol 25:255-261.
10. Friedlander ML, Hedley DW, Taylor IW, Russell P, Coates AS, Tattersall MH (1984): Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res 44:397-400.
11. Holdaway KM, Finlay GJ, Baguley BC (1992): Relationship of cell cycle parameters to in vitro and in vivo chemosensitivity for a series of Lewis lung carcinoma lines. Eur J Cancer 28A:1427-1431.
12. Lock RB, Ross WE (1990): Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells. Cancer Res 50:3761-3766.
13. Marder BA, Morgan WF (1993): Delayed chromosomal instability induced by DNA damage. Mol Cell Biol 13:6667-6677.
14. Milchell ID, Lambert TR, Burden M, Sutherland J, Porter RL, Carlton JB (1995): Is polyploidy an important genotoxic lesion? Mutagenesis 10:79-83.
15. Pommier Y, Kerrigan D, Covey JM, Kao-Shan CS, Whang-Peng J (1988): Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells. Cancer Res 48:512-516.
16. Ralph RK, Judd W, Pommier Y, Kohn KW (1994): DNA topoisomerases. In Neidle S, Waring M (eds): "Topics in Molecular and Structural Biology: Molecular Aspects of Anticancer Drug-DNA Interactions." 1st ed., vol. 2. Kent: Macmillan.
17. Shamu CE, Murray AW (1992): Sister chromatid separation in frog egg extracts requires DNA topoisomerase-II activity during anaphase. J Cell Biol 117:921-934.
18. Slavotinek A, Perry PE, Sumner AT (1993): Micronuclei in neonatal lymphocytes treated with the topoisomerase-II inhibitors amsacrine and etoposide. Mutat Res 319:215-222.
19. Tucker JD, Christensen ML, Carrano AV (1988): Simultaneous identification and banding of human chromosome material in somatic cell hybrids. Cytogenet Cell Genet 48:103-106.